GLP-1 drugs: the honest take on Ozempic & Zepbound
Few topics are as distorted by tribalism as GLP-1 drugs. One camp calls them a cheat or a moral failing; the other treats them as a consequence-free miracle. The evidence supports neither. Semaglutide and tirzepatide are, unambiguously, the most effective pharmacological weight-loss tools ever developed, and they come with real trade-offs that the hype glosses over and the shaming ignores.
What the trials actually show
This is not borderline evidence, it's some of the strongest in the obesity field, from large randomized controlled trials.
In STEP 1, once-weekly semaglutide 2.4 mg produced a mean body-weight reduction of about 15% over 68 weeks, versus ~2.4% for placebo, in nearly 2,000 adults.[1] In SURMOUNT-1, tirzepatide produced mean reductions of 15.0%, 19.5%, and 20.9% at its three doses over 72 weeks, versus 3.1% for placebo.[2] And in the head-to-head SURMOUNT-5, tirzepatide beat semaglutide directly, roughly 20% vs 14% weight loss.[3]
For context: previous weight-loss drugs delivered low-single-digit percentages. This is a categorical leap, not an incremental one.
It's not just weight, there's a cardiovascular signal
The story got more serious with SELECT, which tested semaglutide in people with obesity and established cardiovascular disease but without diabetes. It reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by about 20%.[4] That moves these drugs from "cosmetic" to genuinely disease-modifying for the right patients.
The downsides the hype skips
Powerful is not the same as free. The honest debit column:
- GI side effects, nausea, vomiting, constipation, and reflux are common, especially during dose escalation. Most ease over time; some people can't tolerate them.
- Muscle loss. A meaningful fraction of the weight lost on GLP-1s can be lean mass, not just fat, particularly if protein intake and resistance training are neglected. Losing muscle while losing weight is exactly the wrong body-composition outcome, and it's the single most preventable mistake.[2]
- Regain after stopping. These treat obesity as the chronic condition it is; stop the drug without having built durable habits and weight typically returns.
- Cost and access, and the need for medical supervision and monitoring.
The honest framing
GLP-1s are neither cheating nor magic. Obesity is a biological condition with powerful homeostatic drivers, and these drugs work by turning down the appetite signaling that makes sustained calorie restriction so hard, which is why willpower-based approaches fail so often. Using an effective tool for a medical condition is not a moral failure. But the tool works best as a platform for the fundamentals, not a replacement for them.
Do this alongside (if you use one)
- Prioritize protein, keep intake high (~1.6 g/kg/day) to defend muscle while appetite is suppressed.[2]
- Resistance train, the most direct countermeasure to drug-associated muscle loss.
- Build the habits now, use the appetite quiet to establish food and training patterns that survive after the drug.
- Work with a clinician, dosing, side-effect management, and monitoring are not DIY.
- Treat it as long-term, go in understanding obesity is chronic and regain is the default if you stop without a plan.
FAQ
How much weight? ~15% (semaglutide) to ~21% (tirzepatide) in trials; tirzepatide beat semaglutide head-to-head.
Real downsides? GI side effects, muscle loss if protein/training are neglected, regain after stopping, cost, and need for supervision.
Substitute for diet and exercise? No, they make eating less effortless, but muscle preservation and durable results still require protein, training, and habit change.
References
- 1.Wilding JPH, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine 384(11):989–1002. PMID: 33567185. Link
- 2.Jastreboff AM, et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine 387(3):205–216. PMID: 35658024. Link
- 3.Aronne LJ, et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine. Link
- 4.Lincoff AM, et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine 389(24):2221–2232. PMID: 37952131. Link
This article is for educational purposes only and is not medical advice. It is not a substitute for professional diagnosis, treatment, or the guidance of a qualified clinician. Always consult your physician before changing your diet, starting a fast, taking supplements, or beginning a new training or heat/cold protocol, especially if you are pregnant, breastfeeding, managing a medical condition, or taking medication.